Computational systems for biomedical data

• US 10,095,836 B2
• Filed: 06/22/2007
• Issued: 10/09/2018
• Est. Priority Date: 09/29/2006
• Status: Active Grant

• Current Assignee: Travera, LLC
• Original Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Inventors: Jung, Edward K. Y., Levien, Royce A., Lord, Robert W., Malamud, Mark A., Wood, Jr., Lowell L.
• Primary Examiner(s): Lin, Jerry
• Application Number:
  US11/821,537
• Publication Number:
  US 20080082582A1
• Time in Patent Office: 4,127 Days
• Field of Search: None
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 70/00 ICT specially adapted for the handling or processing of medical references
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

Methods, apparatuses, computer program products, devices and systems are described that are configured for accepting an input identifying at least one treatment target in search of an agent; accessing at least one dataset containing at least one agent for use in the context of the at least one treatment target; applying at least one filter criterion to at least one dataset to identify a subset of the at least one dataset, the subset of the at least one dataset associated with a defined level of at least one adverse event associated with administration of the at least one agent; and presenting the at least one agent in response to the subset of the at least one dataset.

Claims

1. A method comprising:

accepting at least one treatment target pertaining to at least one patient via at least one user interface;

determining, based at least partly on a least one tissue sample from the at least one patient, at least one characteristic of a subpopulation identifier, wherein the at least one characteristic includes at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter;

receiving at least one input indicating at least one minimum level of efficacy for at least one treatment agent;

identifying at least one defined level of incidence of at least one adverse event, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier;

identifying at least one treatment agent and at least one supplemental agent for use in the context of the at least one treatment target and the at least one defined level of incidence, including at least;

applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data;

identifying a list of treatment agent options based at least partly on the defined level of incidence associated with the at least one characteristic of the subpopulation identifier, the at least one level of efficacy, and the identified at least one particular study data; and

identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent; and

transmitting for display on at least one display device the list of treatment options and the corresponding list of supplemental agent options, the options ranked based at least partly on the level of efficacy and the level of incidence when the at least one treatment agent is administered in conjunction with the at least one supplemental agent and correlating the treatment agent options with corresponding supplemental agent options; and

initiating administration of at least a portion of the at least one treatment agent and the at least one supplemental agent to the at least one patient.

2. A system comprising:

at least one electronic device including at least;

circuitry for accepting at least one treatment target pertaining to at least one patient;

circuitry for determining, based at least partly on a least one tissue sample from the at least one patient, at least one characteristic of a subpopulation, wherein the at least one characteristic includes at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter;

circuitry for receiving at least one input indicating at least one minimum level of efficacy for at least one treatment agent;

circuitry for identifying at least one defined level of incidence of at least one adverse event, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier;

circuitry for identifying at least one treatment agent and at least one supplemental agent for use in the context of the at least one treatment target and the at least one defined level of incidence, including at least;

circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data;

circuitry for identifying a list of treatment agent options based at least partly on the defined level of incidence associated with the at least one characteristic of the subpopulation identifier, the at least one level of efficacy, and the identified at least one particular study data; and

circuitry for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent;

circuitry for transmitting for display on at least one display device the list of treatment options and the corresponding list of supplemental agent options, the options ranked based at least partly on the level of efficacy and the level of incidence when the at least one treatment agent is administered in conjunction with the at least one supplemental agent and correlating the treatment agent options with corresponding supplemental agent options; and

circuitry for initiating administration of at least a portion of the at least one treatment agent and the at least one supplemental agent to the at least one patient.

3. The system of claim 2, wherein the circuitry for accepting at least one treatment target pertaining to at least one patient via at least one user interface comprises:

circuitry for accepting at least one of a medical condition treatment target, a nutritional deficiency treatment target, an obesity condition treatment target, a chronic condition treatment target, or an acute condition treatment target as the at least one treatment target.

4. The system of claim 2, wherein the circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data comprises:

circuitry for applying at least the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to at least one clinical trial dataset to identify a subset of the at least one clinical trial dataset, the subset of the at least one clinical trial dataset associated with the at least one characteristic of the subpopulation identifier and the at least one defined level of incidence of the at least one adverse event associated with administration of the at least one agent.

5. The system of claim 2, wherein the circuitry for transmitting for display on at least one display device the list of treatment agents and the corresponding list of supplemental agent options, the options ranked based at least partly on the level of efficacy and the level of incidence comprises:

circuitry for accepting, via the at least one user interface, at least one ranking factor for ranking one or more possible agents for use in treating the at least one treatment target.

6. The system of claim 2, wherein the circuitry for accepting at least one treatment target pertaining to at least one patient via at least one user interface comprises:

circuitry for accepting at least one preferred treatment agent via at least one user interface of a local device, and

wherein the circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data includes at least;

circuitry for selecting particular study data from one or more databases of study data stored on one or more remote devices and accessible by the at least one local device via one or more networks

wherein the circuitry for identifying a list of treatment agent options based at least partly on the defined level of incidence associated with the at least one characteristic of the subpopulation identifier, the at least one level of efficacy, and the identified at least one particular study data includes at least;

circuitry for determining whether the at least one preferred treatment agent meets the at least one level of efficacy and the at least one defined level of incidence, and

wherein the circuitry for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent includes at least;

circuitry for identifying at least one supplemental agent known to at least one of increase the efficacy or decrease the level of incidence of the preferred treatment agent.

7. The system of claim 2, wherein the circuitry for identifying at least one defined level of incidence of at least one adverse event, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier comprises:

circuitry for identifying at least one subpopulation that reports at least one defined level of incidence of the at least one adverse event;

circuitry for determining whether the at least one subpopulation correlates to the at least one characteristic of the subpopulation determined based at least partly on the at least one tissue sample from the at least one patient; and

circuitry for accepting the at least one defined level of incidence based at least partially on the identified at least one subpopulation and the reported at least one defined level of incidence associated with the identified at least one subpopulation.

8. The system of claim 2, wherein the circuitry for identifying at least one defined level of incidence of at least one adverse event interface comprises:

circuitry for identifying at least one defined level of incidence that includes at least one indication of a subjective report of a tolerance level for the at least one adverse event.

9. The system of claim 2, wherein the circuitry for identifying at least one defined level of incidence of at least one adverse event comprises:

circuitry for identifying a level of incidence that includes at least one molecular marker indicative of a defined level of the at least one adverse event;

circuitry for determining whether the at least one molecular marker is present in the at least one tissue sample from the at least one patient, and

wherein the circuitry for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent includes at least;

circuitry for identifying at least one supplemental agent known to have at least one effect associated with the at least one molecular marker indicative of the defined level of the at least one adverse event.

10. The system of claim 2, wherein the circuitry for identifying at least one defined level of incidence of at least one adverse event, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier comprises:

circuitry for identifying at least one subpopulation that reports the at least one defined level of incidence of the at least one adverse event; and

circuitry for determining whether the at least one adverse event is associated with at least one genetic expression common to the at least one subpopulation and the at least one patient, and

wherein the circuitry for identifying at least one treatment agent and at least one supplemental agent for use in the context of the at least one treatment target and the at least one defined level of incidence includes at least;

circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify a subset of the selected particular clinically relevant study data, the subset of the selected particular study data associated with the at least one characteristic of the subpopulation identifier and the at least one defined level of incidence of the at least one adverse event associated with administration of the at least one agent; and

circuitry for identifying at least one agent for use based at least partially on at least one indication of minimum level of efficacy associated with the at least one characteristic of the subpopulation identifier and based at least partially on at least one indication of decreased incidence of the at least one adverse event.

11. The system of claim 2, wherein the circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data comprises:

circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one study conducted on clinically relevant patient populations, the clinical relevance based at least partly on the at least one tissue sample from the at least one patient.

12. The system of claim 11, wherein the circuitry for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one study conducted on clinically relevant patient populations comprises:

circuitry for applying at least one filter criterion to identify study data conducted on populations with at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter characteristic similar to a patient for which the at least one treatment target is intended.

13. The method of claim 2, wherein the circuitry for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent comprises:

circuitry for identifying at least one supplemental agent to be administered during treatment with the identified treatment agents, the at least one supplemental agent associated with decreased incidence of the at least one adverse event in the clinically relevant subpopulation.

15. The system of claim 2, wherein the circuitry for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent comprises:

circuitry for identifying a corresponding list of supplemental agent options known to decrease the level of incidence of the corresponding treatment agents and known to at least one of maintain or improve the efficacy of the corresponding treatment agents.

16. The system of claim 2, wherein the circuitry for transmitting for display on at least one display device the list of treatment agents and the corresponding list of supplemental agent options comprises:

circuitry for displaying, on at least one display of the at least one electronic device, the list of treatment agents and the corresponding list of supplemental agent options.

17. The system of claim 2, wherein the circuitry for determining, based at least partly on a least one tissue sample from the at least one patient, at least one characteristic of a subpopulation, wherein the at least one characteristic includes at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter comprises:

circuitry for determining a particular risk associated with the at least one treatment target and at least one of the genetic expression parameter, the epigenetic expression parameter, or the demographic parameter.

18. The system of claim 2, wherein the circuitry for initiating administration of at least a portion of the at least one treatment agent and the at least one supplemental agent to the at least one patient comprises:

circuitry for initiating administration of a treatment consisting of at least one pharmaceutical agent and at least one non-pharmaceutical agent.

14. A system comprising:

a computing device; and

instructions that when executed on the computing device cause the computing device to perform operations including at least;

accept at least one treatment target pertaining to at least one patient via at least one user interface;

determine, based at least partly on a least one tissue sample from the at least one patient, at least one characteristic of a subpopulation identifier, wherein the at least one characteristic includes at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter;

receive at least one input indicating at least one minimum level of efficacy for at least one treatment agent;

identify at least one defined level of incidence of at least one adverse event, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier;

identify at least one treatment agent and at least one supplemental agent for use in the context of the at least one treatment target and the at least one defined level of incidence, including at least;

apply the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data;

identify a list of treatment agent options based at least partly on the defined level of incidence associated with the at least one characteristic of the subpopulation identifier, the at least one level of efficacy, and the identified at least one particular study data; and

identify a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent;

transmit for display on at least one display device the list of treatment options and the corresponding list of supplemental agent options, the options ranked based at least partly on the level of efficacy and the level of incidence when the at least one treatment agent is administered in conjunction with the at least one supplemental agent and correlating the treatment agent options with corresponding supplemental agent options; and

initiate administration of at least a portion of the at least one treatment agent and the at least one supplemental agent to the at least one patient.

20. The system of claim 14 wherein the computing device comprises:

one or more of a personal digital assistant (PDA), a laptop computer, a tablet personal computer, a networked computer, a computing system comprised of a cluster of processors, a computing system comprised of a cluster of servers, a workstation computer, and/or a desktop computer.

19. A computer program product comprising:

a non-transitory computer-readable medium bearing at least;

one or more instructions for accepting at least one treatment target pertaining to at least one patient via at least one user interface;

one or more instructions for determining, based at least partly on a least one tissue sample from the at least one patient, at least one characteristic of a subpopulation identifier, wherein the at least one characteristic includes at least one of a genetic expression parameter, an epigenetic expression parameter, or a demographic parameter;

one or more instructions for receiving at least one input indicating at least one minimum level of efficacy for at least one treatment agent;

one or more instructions for identifying at least one defined level of incidence of at least one adverse event via the at least one user interface, the defined level of incidence associated with the at least one characteristic of a subpopulation identifier;

one or more instructions for identifying at least one treatment agent and at least one supplemental agent for use in the context of the at least one treatment target and the at least one defined level of incidence, including at least;

one or more instructions for applying the at least one defined level of incidence and the at least one characteristic of the subpopulation identifier to identify at least one particular clinically relevant study data;

one or more instructions for identifying a list of treatment agent options based at least partly on the defined level of incidence associated with the at least one characteristic of the subpopulation identifier, the at least one level of efficacy, and the identified at least one particular study data; and

one or more instructions for identifying a corresponding list of supplemental agent options known to at least one of increase the efficacy or decrease the level of incidence of the at least one treatment agent;

one or more instructions for transmitting for display on at least one display device the list of treatment options and the corresponding list of supplemental agent options, the options ranked based at least partly on the level of efficacy and the level of incidence when the at least one treatment agent is administered in conjunction with the at least one supplemental agent and correlating the treatment agent options with corresponding supplemental agent options; and

one or more instructions for initiating administration of at least a portion of the at least one treatment agent and the at least one supplemental agent to the at least one patient.